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Neonatal sepsis is associated with increased mortality and morbidity including neurodevelopmental impairment and prolonged
hospitalstay.Signsandsymptomsofsepsisarenonspeciﬁc,andempiricantimicrobialtherapyispromptlyinitiatedafterobtaining
appropriate cultures. However, many preterm and low birth weight infants who do not have infection receive antimicrobial
agents during hospital stay. Prolonged and unnecessary use of antimicrobial agents is associated with deleterious eﬀects on the
host and the environment. Traditionally, the choice of antimicrobial agents is based on the local policy, and the duration of
therapy is decided by the treating physician based on clinical symptoms and blood culture results. In this paper, we discuss
brieﬂy the causative organism of neonatal sepsis in both the developed and developing countries. We review the evidence for
appropriate choice of empiric antimicrobial agents and optimal duration of therapy in neonates with suspected sepsis, culture-
proven sepsis, and meningitis. Moreover, there is signiﬁcant similarity between the causative organisms for early- and late-onset
sepsis in developing countries. The choice of antibiotic described in this paper may be more applicable in developed countries.
1.Introduction
Neonatal sepsis is a clinical syndrome characterized by sys-
temic signs of infection and accompanied by bacteremia in
the ﬁrst month of life [1]. Sepsis occurring in the ﬁrst 72
hours of life is deﬁned as early-onset sepsis (EOS) [2]a n d
that occurring beyond 72 hours as late-onset sepsis (LOS).
Neonatal sepsis is associated with signiﬁcant morbidity and
mortality justifying prompt initiation of appropriate em-
pirical antibiotic therapy. Knowledge of both the common
pathogens causing septicemia in neonates and their antimi-
crobial susceptibility is essential in order to select appro-
priate antimicrobial treatment. Antimicrobial susceptibility
patternsofpathogensvarygeographicallyandaretemporally
dependent on local pathogens and patterns of antibiotic use.
The aim of this paper is to review the literature regarding
theappropriatechoiceanddurationofantimicrobialtherapy
for suspected sepsis, culture-proven sepsis, and meningitis
during neonatal period. We would like to focus mainly on
the treatment of bacterial infection.
2. Microbiology of Neonatal Sepsis
The majority of cases of EOS result from vertical trans-
mission of bacteria from mother to the neonate during the
intrapartum period. LOS is due to the horizontal transmis-
sion of pathogens from the environment or the hands of the
caregiver. The pattern of bacterial pathogen responsible for
neonatal sepsis has changed with time and varies from place
to place. There is a diﬀerence in the causative organisms for
neonatal sepsis between the developed and developing coun-
tries [2–9]. Within developing countries, there are regional
variations in the spectrum of organisms causing neonatal
sepsis.
In United States, the National Institute of Child Health
and Development (NICHD) reported that the common
pathogens causing EOS are group B Streptococcus (GBS) and
Escherichiacoli[2].GBSremainsthemostfrequentpathogen
in term infants, and E. coli the most signiﬁcant pathogen
in preterm infants with EOS [2]. Similarly, a study from
the United Kingdom has reported GBS to be the most2 International Journal of Pediatrics
Table 1: Randomized controlled trials on empirical antimicrobial therapy for suspected early-onset sepsis.
Author Population Antibiotics used Duration of treatment Outcomes Result
Snelling et al.,
1983 [19]
55 neonates <48
hours old with
suspected sepsis
Ceftazidime (n = 31)
versus gentamicin plus
benzyl penicillin
(n = 24)
48 hours if culture was
sterile. 7 days if culture
was positive or infant
symptomatic
Mortality, treatment
failure, bacteriological
resistance
Ceftazidime is
good as penicillin
and gentamicin
Miall-Allen et al.,
1988 [20]
72 neonates <48
hours old with
suspected sepsis
Timentin (ticarcillin +
clavulanic acid) (n = 32)
versus piperacillin ±
gentamicin (n = 40)
Variable based on
clinical and bacterial
remission. Maximum 10
days
Mortality, treatment
failure, bacteriological
resistance
No diﬀerence in
mortality or
treatment failure
Metsvaht et al.,
2010 [21]
283 neonates <72
hours old with
suspected sepsis
Ampicillin + gentamicin
(n = 142) versus
penicillin + gentamicin
(n = 141)
Not speciﬁed
Treatment failure
( d e ﬁ n e da sn e e df o ra
change in the initial
antibiotic regimen
within 72h and/or
7-day all-cause
mortality)
No diﬀerence in
treatment failure
or mortality rate
between the two
regimens
frequent pathogen (31%) followed by coagulase-negative
Staphylococcus (CoNS), nonpyogenic streptococci and E. coli
[3].
In the developed countries, Gram-positive organisms
account for about 70% of all LOS. The common pathogens
causing LOS in very low birth weight (VLBW) infants
include CoNS followed by Staphylococcus aureus, Enterococ-
cus spp., and GBS [3–5]. About 18–20% of late-onset sepsis
is caused by Gram-negative organisms especially Enterobac-
teriaceae spp. and E. coli. About 12% of LOS sepsis is caused
by fungi especially Candida species [4].
In the developing world, E. coli, Klebsiella species,a n dS.
aureus are the most common pathogens of EOS, whereas S.
aureus, Streptococcus pneumonia,a n dStreptococcus pyogenes
are the most commonly reported organisms in LOS [6, 7].
According to the National Neonatal Perinatal Database of
India, Klebsiella pneumonia, Staphylococcus aureus,a n dE.
coli are the three most common organisms causing neonatal
sepsis both in hospital and community [8]. Moreover, the
causative organisms of EOS and LOS sepsis are similar
especially in hospital setting in developing country [9].
3. Empirical AntimicrobialTherapy for
Neonatal Sepsis
Although isolation of a pathogen in culture is a prerequisite
for proven bacterial sepsis, culture results take at least 48–72
hours to be reported. The early and appropriate initiation of
antimicrobial agents in high-risk neonates before the result
of blood culture susceptibility is deﬁned as “empirical antibi-
otictherapy.”Mostinfantsadmittedtotheneonatalintensive
care units (NICUs) receive empirical antibiotics when in
fact the incidence of culture-proven EOS is only between
1 and 4.6 cases per 1000 live births [10, 11]. The clinical
manifestations of neonatal sepsis are nonspeciﬁc, and the
fear of missing the diagnosis is high because of the increased
morbidity and mortality associated with sepsis. One study
noted that the ratio of noninfected to blood-culture-positive
neonatestreatedwithantibioticswasbetween15:1and28:1
[12]. Early and prompt empirical antibiotic therapy, based
on risk-factor-driven decision in EOS [13, 14] and clinical
symptoms in LOS [15], have been shown to reduce mortality
in neonates. The risk factors for EOS include clinical
chorioamnionitis, maternal intrapartum fever (>38.0◦C),
delivery at <37 weeks, rupture of membranes (ROM) >18
hours before delivery, maternal GBS colonization, previous
infant with GBS infection, GBS bacteriuria, and inadequate
intrapartum antibiotic prophylaxis [16]. Among infants who
are discharged home, new onset of fever, cough, fast or
diﬃcult breathing, poor feeding, lethargy, and convulsions
are indicators of sepsis and warrant initiation of appropriate
antibiotic therapy [17].
3.1. Empirical Antimicrobial Regimen for Early-Onset Sepsis.
Treatment of neonates with suspected sepsis or meningitis
should commence as soon as appropriate cultures and in-
travenous access can be obtained. The initial choice of anti-
microbial agents for empirical treatment is dependent on the
knowledge of the probable pathogens based on the perinatal
history, including any maternal symptoms, cultures, or
instrumentation and susceptibility pattern of the organisms
[18].
Prospective randomized controlled trials (RCTs) on the
appropriate choice of antimicrobial therapy in the neonate
with suspected sepsis are limited [19]. Table 1 summarizes
the RCTs on appropriate empirical antimicrobial treatment
options in EOS. Cochrane meta-analysis of 2 RCTs by
Snelling et al. [19] and Miall-Allen et al. [20] that compared
monotherapy to combination antimicrobial therapy failed to
show that one regime was superior to the other [13]. There
was no signiﬁcant diﬀerence in mortality, treatment failure,
or bacteriological resistance. These two trials had small
sample size and were done prior to 1990, and the antibiotics
usedinthestudy(ceftazidime,timentin,andpiperacillin)are
nolongerusedinempiricaltherapytoday.Thismeta-analysis
excluded 12 trials comparing various combinations of
antibiotic therapy due to two reasons: the study population
enrolled neonates older than 48 hours or even olderInternational Journal of Pediatrics 3
children and a distinction between EOS, and LOS was not
made.
Inanopenlabelclusterrandomizedstudy,Metsvahtetal.
[21]fromEstoniacomparedtheclinicaleﬃcacyofampicillin
versus penicillin G both combined with gentamicin in the
empirical treatment of neonates (n = 283) at risk of EOS.
Incidence of proven EOS was 4.9% in this study. The clinical
f a i l u r er a t ew a sn o td i ﬀerent between the two groups (14.1%
versus 14.2%).
In the NICHD neonatal network study [2], all GBS iso-
lates were sensitive to penicillin, ampicillin, and vancomycin.
Among E. coli isolates, 96% were sensitive to gentamicin and
cephalosporin, but up to 78% were resistant to ampicillin.
The national laboratory surveillance data from England and
Wales showed that nearly all (94%) of the early-onset isolates
(GBS, CoNS, nonpyogenic streptococci, E. coli,e t c . )w e r es e n -
sitive to an antibiotic regimen of penicillin + gentamicin and
100% were sensitive to the combination of amoxicillin +
cefotaxime [3].
Based on the common antibiotic susceptibilities of the
predominant organism causing EOS, the recommended in-
itial empiric therapy for a neonate with suspected bacterial
sepsis and/or meningitis includes ampicillin and an amino-
glycoside [22, 23]. This combination expands the antimicro-
bialspectrumandalsooﬀerssynergisticbacterialkilling.The
other advantages are low cost and low rates of emergence of
bacterial resistance [24].
However, in developing countries where the causative
organismsofEOSarediﬀerentfromthedevelopedcountries,
theabovecombinationofampicillinandgentamicinmaynot
be the best empirical antibiotic of choice. Recently, Lubell
etal.[25]reviewedtheliteratureregardingtheantibioticsus-
ceptibility patterns of community-acquired pathogens caus-
ing neonatal sepsis in sub-Saharan Africa and Asia. The two
common pathogens, S. aureus and Klebsiella spp., exhibited
high rates of resistance to almost all commonly used antibi-
otics (ampicillin, ceftriaxone, chloramphenicol, cotrimoxa-
zole, macrolides, and gentamicin). Only Streptococcus pneu-
moniae exhibited good susceptibility to all drugs other than
cotrimoxazole. The available studies from developing world
focus mainly on community-acquired infections, and segre-
gation between EOS and LOS is often not available. More
than 99% of neonatal deaths occur in the developing world,
and a quarter of these deaths are attributed to neonatal sepsis
[26]. Insuﬃcient knowledge about the appropriate antibiotic
choice and the emerging resistance to commonly prescribed
antimicrobials in neonatal sepsis will hamper the ability to
successfully treat this condition in the developing world.
In summary, based on current available evidence, the
combination of ampicillin and gentamicin is an appropriate
choice for empirical therapy of EOS in neonates, where GBS
and E. coli continue to be the predominant organisms. In
developing countries, empiric antibiotic therapy should be
based individualized for each hospital or region.
3.2. Empirical Antimicrobial Therapy for Suspected Late-Onset
Sepsis. As discussed earlier, CoNS is the most common
pathogeninL OSfollowedbyS.aureus,Enterococcusspp.,and
GBS; Gram-negative organisms account for 18–20% of LOS
[3–5]. The empirical antimicrobial therapy for LOS should
cover both Gram-positive and Gram-negative organisms.
In the study from the United Kingdom, more than 95%
of organisms causing LOS were susceptible to gentamicin
with either ﬂucloxacillin or amoxicillin and amoxicillin with
cefotaxime, but only 79% were susceptible to cefotaxime
monotherapy [3].
In the developed countries, where CoNS is the predomi-
nant nosocomial pathogen and where resistance of these iso-
lates to penicillin, semisynthetic penicillin, and gentamicin
are common, experts recommend the use of vancomycin as
empirical therapy [24]. Of the 18 participating NICUs in
Australasian study group for neonatal infection, nine units
used vancomycin and an aminoglycoside as the ﬁrst-line
empirical treatment for LOS [5]. Their mortality from CoNS
sepsis was no diﬀerent from the remaining units that used
ampicillin or ﬂucloxacillin together with an aminoglycoside.
Theauthorssuggestthatovervigorousattemptstoreducethe
incidence of CoNS infections using prophylactic antibiotics
are not advisable as the majority of these infections are
relatively benign.
To reduce the growing emergence of resistant strains
due to injudicious use of vancomycin, Karlowicz et al. [27]
studiedtheimpactofchangingempiricantibiotictherapyfor
LOS from vancomycin and cefotaxime to oxacillin and gen-
tamicin. There was no impact on the frequency of fulminant
sepsis due to CoNS even though 85% of CoNS isolates were
resistant to either oxacillin or gentamicin. Most cases of ful-
minant LOSwerecausedbyGram-negative organisms rather
than CoNS. Similar ﬁndings were reported by Stoll et al. [4].
In developing nations, LOS is complicated by a higher
percentage of Gram-negative bacteria and greater antimi-
crobial resistance among the organisms. Zaidi et al. [28]
reported that the rates of neonatal sepsis were 3–20 times
higher among hospitalized infants in developing countries
comparedtodevelopednations.Klebsiellapneumoniae,other
Gram-negative rods (E. coli, Pseudomonas spp., and Acineto-
bacter spp.), and S. aureus were the major pathogens among
11471 bloodstream isolates. About 70% of these isolates
may not be covered by the empiric regimen of ampicillin
and gentamicin. About half of E. coli and Klebsiella isolates
were resistant to cefotaxime, a commonly used second-line
antibiotic. The important concern is the high proportion of
methicillin-resistant S. aureus (MRSA) strains in many areas,
especially south Asia where 56% of all isolates were reported
to be methicillin resistant.
The Cochrane review of empirical antibiotic therapy in
LOS [29] included one study by Miall-Allen et al. [20] that
compared timentin (ticarcillin and clavulanic acid) mono-
therapy with a combination of ﬂucloxacillin and gentamicin
in 28 neonates with suspected LOS. Although the study did
notmeetthecriteriaformethodologicalquality,therewasno
diﬀerence in outcome (mortality/treatment failure) between
the two groups.
Empiric antifungal therapy should be considered if the
infants have central vascular access, an endotracheal tube,
thrombocytopenia (<100,000/mm3), exposure to broad-
spectrumcephalosporinsorcarbapenem,andgestationalage4 International Journal of Pediatrics
lessthan28weeks[30,31].AmphotericinBshouldbechosen
for empiric therapy, and ﬂuconazole should be reserved for
prophylaxis.
In summary, there is inadequate evidence from random-
ized trials in favor of any particular antimicrobial regimen
for the empirical treatment of suspected LOS. An acceptable
approach would be to start with cloxacillin and gentamicin
as initial antibiotics for LOS in a stable neonate. Vancomycin
and third-generation cephalosporin (e.g., cefotaxime) should
be considered for LOS in a neonate presenting with cardi-
orespiratory instability and in areas where MRSA is prev-
alent. The dangers of starting vancomycin as the initial
therapy in all infants include the risk of emergence of van-
comycin-resistant enterococci and its overuse in cases where
CoNS isolates represent mere contaminants.
4. DurationofEmpiricalAntimicrobialTherapy
There is a wide variation between centers regarding the
appropriate duration of empiric antibiotics for suspected
EOSwhenblood culturesarenegative [32]. This is more per-
tinent for preterm infants (gestational age <34 weeks and/or
<1500 grams) as they are considered to be at high risk for
sepsis, and the usual practice is to draw appropriate cultures
and start antibiotics. The recommendations for treatment of
infants with suspected sepsis but who have negative cultures
are not based on strong evidence. The standard practice
is to discontinue antibiotics as soon as blood cultures are
conﬁrmed negative (48–72 hours) and there are no clinical
or hematologic signs of infection [32–34]. This recommen-
dation is originally based on Pichichero’s study [35]w h o
reported that 96% of bacteremic cultures drawn prior to an-
tibiotic therapy are positive by 48 hours and 98% are positive
by 72 hours.
With the use of computer-assisted automated culture
media (the ESP blood culture system), Garcia-Prats et al.
[36] reported that 89% of blood cultures of potentially septic
neonates (term and preterm) become positive by 36 hours
and 94% by 48 hours. The time to blood culture positivity
was not aﬀected by prior antibiotic therapy. The authors
concluded that, in term asymptomatic infants treated with
antibiotics based on maternal risk factors, the duration can
be reduced to 24–36 hours where reliable and speedier blood
culture results are available.
There is a lack of well-designed adequately powered trials
evaluating the appropriate duration of empirical antimi-
crobial therapy in blood-culture-negative sepsis. The only
pilot study by Saini et al. [37] randomized 52 infants (>30
weeks gestation and >1000g at birth), with culture-negative
probable sepsis to either short-course (48–96 hours) or long-
course (7 days) antibiotic therapy. The randomization was
done 48–72 hours after enrollment. Infants with conﬁrmed
sepsis and those who had persisting clinical symptoms were
excluded. The choice of antibiotic therapy (cephalosporin,
amikacin, and cloxacillin) was made by the treating physi-
cian. There was no diﬀerence in treatment failure (deﬁned
as reappearance of signs of sepsis within 15 days of stopping
antibiotics, supported by laboratory evidence) rate between
the 2 groups. The limitations of this study include its small
sample size, lack of segregation between early- and late-onset
sepsis, and the exclusion of smaller babies.
CorderoandAyers[38]reportedthatitisprobablysafeto
discontinue empiric antibiotics when blood cultures are neg-
ative in asymptomatic extremely low birth weight (ELBW)
neonates. They noted that ELBW infants treated with a
shortercourse(≤3days)forsuspectedsepsishadlesserexpo-
sure to a third antimicrobial (vancomycin, amphotericin, or
oxacillin) and lesser antibiotic days compared to a longer
course (≥7 days).
Althoughprospectivestudiesarelimited,itseemsreason-
able to conclude that the duration of empirical antimicrobial
therapy should be 48–72 hours pending culture results for
suspected neonatal sepsis. A symptomatic baby can have a
false-negative blood culture if antibiotics are given prenatally
to the mother or if the blood sample is collected improperly.
Hence, antibiotics should be continued for symptomatic
infants and those with positive blood culture.
5. Role of C-Reactive ProteininGuiding
the Duration of AntimicrobialTherapy
C-reactive protein (CRP) is an excellent marker for estab-
lished neonatal bacterial infections. However, it is not useful
for early diagnosis because levels are elevated only in 35% to
65% of neonates at the onset of illness [39]. Several studies
have evaluated the role of serial CRP measurement as a guide
to the duration of antibiotic therapy both in developed and
developing countries [40–44]. Serial CRP values taken 24–
48haftertheonsetofsymptomshaveanimprovedsensitivity
andspeciﬁcitywhencomparedwithsingleCRPvaluesatpre-
sentation for diagnosis of sepsis. Two consecutive CRP levels
<10mg/L24hoursapart,8–48hoursafterpresentation,have
a negative predictive value for sepsis of 99% [40].
Philip and Mills [41] suggested that normalization of
CRP levels can be considered as a criterion for the discontin-
uation of antibiotic therapy to minimize antibiotic exposure
and shorten hospital stay. In a prospective study, Ehl et al.
[42] observed that CRP levels of <10mg/L determined 24
hours after beginning antibiotic treatment correctly identi-
ﬁed 120 of 121 infants as not needing further antibiotics.
Jaswal et al. [43] reported a 100% negative predictive value
with no relapse following discontinuation of antibiotic treat-
ment after normalization of CRP levels. Contrary to the
previous studies, Al-Zwaini et al. [44]r e p o r t e dC R Pt ob e
a poor guide for the duration of treatment in neonatal septi-
cemia, with modest sensitivity and negative predictive value
(78% and 86%, resp.) at 48 hours following initiation of
antibiotics.
The physicians are in constant dilemma regarding the
duration of antibiotic therapy in neonates with likely infec-
tion who have nonspeciﬁc clinical symptoms and negative
blood cultures or those infants who undergo incomplete
sepsis workup. In such cases, Squire et al. [45]s u g g e s t e d
that, by augmenting the sepsis evaluation with a negative
CRP, total antibiotic use may be reduced by up to 20% for
the entire nursery. However, previous studies that showed
CRP as a good guide excluded high-risk infants with central
lines, mechanical ventilation, postsurgery, meningitis, birthInternational Journal of Pediatrics 5
Table 2: Randomized controlled trials of short- versus long-course antibiotic therapy in neonatal bacterial sepsis/pneumonia.
Author Population Antibiotics used Duration of
treatment Outcomes Conclusion
Engle et al., 2000
[53]
Term and near-term
neonates with pneumonia.
Excluded babies with
meconium stained
amniotic ﬂuid and O2
requirement for >8h o u r s .
Ampicillin and
gentamicin
4d a y s( n = 35)
versus
7d a y s( n = 38)
Success deﬁned as
neonates doing well
after discharge and no
need for
rehospitalization for
sepsis or pneumonia
The success rate for
therapy was similar
between the two groups
Chowdhary et al.,
2006 [54]
≥32 weeks and >1500
grams with positive blood
culture.
Excluded deep seated
infections and meningitis
Not speciﬁed
7d a y s( n = 34)
versus
14 days (n = 35)
Treatment failure
within 28 days
There was a trend
towards more treatment
failures in 7-day group
as compared to 14-day
group (5 infants versus 1
infant, P = 0.19)
Gathwala et al.,
2010 [55]
Infants ≥32 weeks and
>1500 grams with positive
blood culture.
Excluded deep seated
infections and meningitis
Cefotaxime and
amikacin
10 days (n = 30)
versus
14 days (n = 30)
Treatment failure
within 28 days
10-day course was as
eﬀective as 14-day
course in
blood-culture-proven
neonatal
asphyxia [42], and those with positive initial CRP [40].
Hence, the usefulness of CRP in guiding decisions regarding
the duration of antibiotics might be valid only in selected
subset of neonates.
6. Hazardsof Prolonged Empirical
AntimicrobialTherapy
Optimal duration of empiric antimicrobial use decreases the
development of antimicrobial resistance, prevents unwanted
changes in ﬂora found in the NICU, and minimizes unneces-
sary expenses for infants who have negative blood cultures
[46, 47]. About half of all ELBW infants receive empirical
antibiotics for prolonged periods (>3–5 days) despite neg-
ative blood cultures [47, 48]. Prolonged duration of initial
empirical antibiotic therapy is associated with an increased
risk of necrotizing enterocolitis and death in ELBW infants
[48]. Clark et al. [49] observed that selection of cefotaxime
(a third-generation cephalosporin) instead of gentamicin for
the ﬁrst 3 postnatal days is associated with higher mortality
rate, even for the most preterm infants. Other adverse eﬀects
of prolonged empirical antibiotic therapy include increased
risk of neonatal candidiasis with the use of cephalosporins
[50, 51] and alteration of gut microﬂora [52]. Hence, it
seems prudent to restrict the duration of empirical antibiotic
therapy to <3 days when blood cultures are sterile and baby
is asymptomatic.
7. Duration of Antimicrobial Therapy for
ProvenBacterial SepsiswithoutMeningitis
The duration of antimicrobial therapy for culture-proven
sepsis depends on the initial response to the appropriate
antimicrobial agent. In the chapter on bacterial sepsis and
meningitis, Klein recommend 10 days of therapy for culture-
proven sepsis with minimal or absent focal infection [22].
However, there is a paucity of RCTs evaluating the rationale
and safety of the appropriate duration of therapy [53–55].
Table 2 describes the RCTs evaluating shorter versus longer
courses of antibiotic therapy in neonatal pneumonia and
culture-proven sepsis.
Engle et al. [53] randomized cases of neonatal pneumo-
nia to either 4-day or 7-day course of antibiotics. Randomi-
zation was done on day 4 of antibiotic therapy if the infants
were completely asymptomatic for at least 48 hours. Infants
in the 4-day course wereobserved for 24 hours afterstopping
antibioticsandwerereassessedasoutpatientswithin2-3days
following discharge. The success of therapy, as deﬁned by
infants doing well after discharge and no need for rehospi-
talization for sepsis or pneumonia, was similar in both the
groups, and the length of hospitalization was shorter in 4-
day therapy.
Chowdhary et al. [54] compared the eﬀectiveness of 7-
day versus 14-day antibiotic therapy in 69 infants with blood
culture-proven bacterial sepsis (without meningitis and deep
seated infections). Randomization to either 7-day or 14-day
therapy was performed on day 7 of antibiotics if the infant
had clinical remission by day 5. Blood culture was repeated
24 hours after antibiotic completion, and infants were
observed in the hospital for at least 72 hours and followed up
for 28 days. There was a trend towards more treatment fail-
ures (deﬁned as a positive blood culture, or clinical signs) in
7-day group as compared to 14-day group (5 infants versus 1
infant, P = 0.19). Subgroup analysis revealed that treatment
failures occurred in subjects with S. aureus infection receiv-
ing 7-day course (4 infants). S. aureus accounted for 20%
positive cultures. The authors concluded that neonates with
S. aureus infection may require 14 days of antibiotic therapy.
Gathwala et al. [55] compared the eﬀectiveness of a
10-day versus 14-day course of antibiotic therapy in blood
culture-proven neonatal sepsis. Sixty infants were ran-
domized on day 7 of antibiotic therapy, if they were in6 International Journal of Pediatrics
clinical remission with negative C-reactive protein (CRP).
Cefotaxime and amikacin were used in all infants. The
most common organism causing sepsis was Pseudomonas
aeruginosa in both of the groups, followed by Acinetobacter
and Klebsiella. The incidence of CoNS and S. aureus was
3% and 8%, respectively. The primary outcome of treatment
failure within 28 days occurred in one infant in each group.
The duration of hospital stay was signiﬁcantly shorter in the
10-day course as compared with the 14-day course (13 ± 1.7
days versus 17 ± 2.2 days). They concluded that 10-day
antibiotic therapy is as eﬀective as 14-day therapy in blood-
culture-proven neonatal sepsis, if the infant has achieved
clinical remission by day 7 of therapy.
In the above 3 trials, the participants were ≥32 weeks
or ≥1500 grams and were in clinical remission at the time
of randomization. There is limited evidence for infants with
younger gestational age (<32 weeks), who are at the highest
risk for sepsis. In other words, the shorter duration seemed
eﬀective only in selected subset of neonates who were at least
32 weeks and above and showed good initial response to
antibiotics (milder disease).
In summary, pending further evidence, it is reasonable
to treat for 10–14 days with appropriate antimicrobial
agents in infants with blood-culture-proven sepsis. However,
in selected situations (neonates ≥32 weeks gestation and
≥1500 grams, who become asymptomatic within 5 days of
appropriate therapy), we can consider stopping antibiotics at
7–10 days, provided appropriate followup can be ensured.
8. AntimicrobialChoice andDuration of
Therapy for Neonatal Meningitis
Decisions on the choice of a speciﬁc antimicrobial agent
are based on knowledge of its activity against the causative
pathogen and relative penetration into cerebrospinal ﬂuid
(CSF) in the presence of meningeal inﬂammation. In 2004,
Infectious Disease Society of America published practice
guidelines for treatment of meningitis [56]. When bacterial
meningitis is suspected as part of EOS, ampicillin with
either an aminoglycoside or cefotaxime is commonly rec-
ommended as initial empirical therapy to cover GBS, E.
coli, Listeria monocytogenes,a n dKlebsiella species [56]. For
neonates with late-onset meningitis, a regimen containing
an antistaphylococcal antibiotic, such as nafcillin or van-
comycin, plus cefotaxime or ceftazidime with or without an
aminoglycoside is recommended [57].
Theduration ofantimicrobial therapyin thepatient with
bacterial meningitis has often been based more on tradition
than on evidence-based data. GBS meningitis is usually
treated for 14 to 21 days, assuming prompt eradication of
bacteriafromtheCSF.Foruncomplicatedneonatalmeningi-
tis caused by Gram-negative bacteria, a minimum of 21 days
is recommended [56].
However, these guidelines are not standardized and the
duration of therapy may need to be individualized on the
basis of the patient’s clinical response. Failure to achieve CSF
sterilization or persistence of symptoms should prompt the
clinicians to look for possible complications such as brain
abscess, ventriculitis, or subdural empyema. Infants with
intracranial abscesses should be treated with a combination
of surgical aspiration or drainage of the abscess plus antimi-
crobial therapy for 4–6 weeks [58]. Early neuroimaging
by ultrasonography, magnetic resonance imaging (MRI), or
computed tomography (CT) is indicated to assess the need
for surgical intervention. Imaging should be repeated even
after the antibiotic therapy has been completed, as there are
reports of abscesses being identiﬁed weeks after the initiation
ofantibiotic therapy.Despiteadequateantimicrobialtherapy
for 21 days or more, relapses may occur in meningitis caused
by Gram-negative enteric bacilli [59].
A systematic review of short-course antibiotic therapy
for meningitis in children (3 weeks to 16 years) showed that
there was no diﬀerence between short-course (4–7 days) and
long-course (7–14 days) treatment (intravenous ceftriaxone)
regarding end of therapy clinical success, long term neu-
rological complications, hearing impairment, or secondary
nosocomial infections [60]. The duration of hospitalization
was lesser with short-course regimen. The antibiotic used
was ceftriaxone in all the 5 studies included in the systematic
review. The CSF concentration of ceftriaxone is many times
higher than the minimum inhibitory concentration for
most causative pathogens [61]. In neonates, cefotaxime is
often preferred over ceftriaxone (particularly for those who
have hyperbilirubinemia) because ceftriaxone can displace
bilirubin from albumin binding sites. Moreover, the patients
enrolled in the above trials were at least 3 months old (except
for one study that enrolled from 3 weeks onwards). Hence,
the result of the systematic review cannot be extrapolated to
neonates who constitute a diﬀerent subset by virtue of their
compromised immune status. Finally, the shorter courses
may not be applicable for patients who receive adjuvant
therapy with dexamethasone. The potential suppression of
immune responses caused by dexamethasone may warrant a
relatively long duration of antimicrobial therapy for optimal
microbiological outcomes [60].
In one RCT, there was no clinical beneﬁt of adjuvant
dexamethasone therapy in 52 full-term neonates with bacte-
rial meningitis [62]. However, a prospective nonrandomized
study from Nigeria reported that dexamethasone signiﬁ-
cantly decreased the mortality and neurological sequelae in
neonatal bacterial meningitis. At present, there is insuﬃcient
data to make a recommendation on the use of adjunctive
dexamethasone in neonatal bacterial meningitis [56].
Repeat lumbar puncture to document CSF sterilization
and improvement of CSF parameters is not indicated rou-
tinely [56]. However, it should be done in all patients who
have not responded clinically after 48 hours of appropri-
ate antimicrobial therapy. Neonates with meningitis due
to Gram-negative bacilli should undergo repeated lumbar
punctures to document CSF sterilization, because the dura-
tion of antimicrobial therapy is determined, in part, by the
result. Some authors recommend CSF examination at the
completion of therapy for all neonates to establish whether
additionaltreatmentisrequiredbecauseoftheunpredictable
clinical course of illness and the unreliability of the clinical
examination in assessment of response to treatment in
neonates [57].International Journal of Pediatrics 7
In summary, combination of ampicillin and cefotaxime
or ampicillin and aminoglycoside is appropriate for treat-
ment of suspected early-onset neonatal meningitis. For sus-
pected late-onset meningitis, a combination of vancomycin
plusathird-generationcephalosporinisrecommendedwhile
awaiting CSF culture and susceptibility results. The duration
of antimicrobial therapy for neonatal meningitis should be
14 to 21 days for GBS, ≥21 days for L. monocytogenes menin-
gitis,andminimumof21daysforGram-negativemeningitis.
9. Conclusion
The choice of antibiotics should be based on the causative
organisms and the patterns of antibiotic susceptibility. The
combination of ampicillin and gentamicin is an appropriate
choice for empirical therapy of neonatal EOS in developed
c o u n t r i e sw h e r eG B Sa n dE. coli continue to be the predomi-
nant organisms. For LOS, starting cloxacillin and gentamicin
may be appropriate in a stable neonate. Vancomycin and
cefotaxime should be considered in sick neonates with car-
diorespiratory compromise and in areas where the MRSA is
prevalent. In developing nations where the causative organ-
isms and pattern of antibiotic susceptibility are diﬀerent, the
choice of antimicrobial therapy should be modiﬁed based on
local prevalence.
The duration of empirical antibiotic therapy in neonates
should be 48–72 hours pending culture results for suspected
sepsis. Until further evidence, the current recommendation
of 10–14 days of antimicrobial treatment is appropriate for
blood-culture-positive sepsis without meningitis. Neonates
with bacterial meningitis require longer duration based on
the organism isolated. Repeat lumbar puncture to document
CSF sterilization is important because of unpredictable clini-
cal course in neonates. Above all a disciplined approach con-
sisting of a thorough physical examination and evaluation
of clinical response to treatment are important in tailoring
appropriatedoseanddurationofantibioticsinneonateswith
suspected or proven sepsis.
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